Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of C$1.44 and traded as high as C$1.74. Oncolytics Biotech shares last traded at C$1.68, with a volume of 175,570 shares.
Analyst Ratings Changes
Separately, Raymond James upped their target price on Oncolytics Biotech from C$3.00 to C$3.50 in a research report on Friday, September 20th.
Get Our Latest Research Report on Oncolytics Biotech
Oncolytics Biotech Price Performance
The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The stock has a market capitalization of C$132.97 million, a PE ratio of -4.55 and a beta of 1.35. The stock's 50 day moving average is C$1.42 and its two-hundred day moving average is C$1.44.
Oncolytics Biotech (TSE:ONC - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The company reported C($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of C($0.10). On average, equities analysts anticipate that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
